You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial
|
|---|---|
| Published in |
Arthritis Research & Therapy, August 2018
|
| DOI | 10.1186/s13075-018-1667-z |
| Pubmed ID | |
| Authors |
Tanja Alexandra Stamm, Klaus Peter Machold, Daniel Aletaha, Farideh Alasti, Peter Lipsky, David Pisetsky, Robert Landewe, Desiree van der Heijde, Alexandre Sepriano, Martin Aringer, Dimitri Boumpas, Gerd Burmester, Maurizio Cutolo, Wolfgang Ebner, Winfried Graninger, Tom Huizinga, Georg Schett, Hendrik Schulze-Koops, Paul-Peter Tak, Emilio Martin-Mola, Ferdinand Breedveld, Josef Smolen |
| Abstract |
In the present study, we explored the effects of immediate induction therapy with the anti-tumour necrosis factor (TNF)α antibody infliximab (IFX) plus methotrexate (MTX) compared with MTX alone and with placebo (PL) in patients with very early inflammatory arthritis. In an investigator-initiated, double-blind, randomised, placebo-controlled, multi-centre trial (ISRCTN21272423, http://www.isrctn.com/ISRCTN21272423 ), patients with synovitis of 12 weeks duration in at least two joints underwent 1 year of treatment with IFX in combination with MTX, MTX monotherapy, or PL randomised in a 2:2:1 ratio. The primary endpoint was clinical remission after 1 year (sustained for at least two consecutive visits 8 weeks apart) with remission defined as no swollen joints, 0-2 tender joints, and an acute-phase reactant within the normal range. Ninety patients participated in the present study. At week 54 (primary endpoint), 32% of the patients in the IFX + MTX group achieved sustained remission compared with 14% on MTX alone and 0% on PL. This difference (p < 0.05 over all three groups) was statistically significant for IFX + MTX vs PL (p < 0.05), but not for IFX + MTX vs MTX (p = 0.10), nor for MTX vs PL (p = 0.31). Remission was maintained during the second year on no therapy in 75% of the IFX + MTX patients compared with 20% of the MTX-only patients. These results indicate that patients with early arthritis can benefit from induction therapy with anti-TNF plus MTX compared with MTX alone, suggesting that intensive treatment can alter the disease evolution. The trial was registered at http://www.isrctn.com/ISRCTN21272423 on 4 October 2007 (date applied)/12 December 2007 (date assigned). The first patient was included on 24 October 2007. |
X Demographics
The data shown below were collected from the profiles of 13 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 2 | 15% |
| United States | 2 | 15% |
| Portugal | 2 | 15% |
| Venezuela, Bolivarian Republic of | 1 | 8% |
| Brazil | 1 | 8% |
| Mexico | 1 | 8% |
| Unknown | 4 | 31% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 10 | 77% |
| Practitioners (doctors, other healthcare professionals) | 2 | 15% |
| Science communicators (journalists, bloggers, editors) | 1 | 8% |
Mendeley readers
The data shown below were compiled from readership statistics for 49 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 49 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 9 | 18% |
| Student > Ph. D. Student | 8 | 16% |
| Researcher | 5 | 10% |
| Professor | 3 | 6% |
| Student > Master | 3 | 6% |
| Other | 7 | 14% |
| Unknown | 14 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 19 | 39% |
| Nursing and Health Professions | 4 | 8% |
| Arts and Humanities | 2 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 4% |
| Psychology | 2 | 4% |
| Other | 2 | 4% |
| Unknown | 18 | 37% |
Attention Score in Context
This research output has an Altmetric Attention Score of 23. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 September 2018.
All research outputs
#1,649,427
of 25,385,509 outputs
Outputs from Arthritis Research & Therapy
#224
of 3,381 outputs
Outputs of similar age
#33,681
of 341,399 outputs
Outputs of similar age from Arthritis Research & Therapy
#8
of 67 outputs
Altmetric has tracked 25,385,509 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,381 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.2. This one has done particularly well, scoring higher than 93% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 341,399 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 67 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 88% of its contemporaries.